Novel targeted therapies for immunoglobulin light chain amyloidosis: latest updates from the 2024 ASH annual meeting

Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by monoclonal plasma cells. The key to treatment is to achieve a deep hematologic remission in order to improve organ function or reverse organ dysf...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of hematology and oncology Jg. 18; H. 1; S. 28 - 4
Hauptverfasser: Bu, Qiling, Zhu, Hong-Hu, Chen, Wenming
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London BioMed Central 07.03.2025
BioMed Central Ltd
Springer Nature B.V
BMC
Schlagworte:
Amyloid
Amyloidosis
Antigens
Cancer Research
Clinical trials
Conferences, meetings and seminars
Correspondence
Drug dosages
Hematology
Humans
Immunoglobulin light chain amyloidosis
Immunoglobulin Light Chains - metabolism
Immunoglobulin Light-chain Amyloidosis - drug therapy
Immunoglobulin Light-chain Amyloidosis - therapy
Immunoglobulins
Latest updates from major conferences
Light
Light chains
Medicine
Medicine & Public Health
Molecular Targeted Therapy - methods
Monoclonal antibodies
Multiple myeloma
Oncology
Peptides
Plasma cells
Remission
Response rates
Targeted therapies
Targeted therapies
Clinical trials
Immunoglobulin light chain amyloidosis
ISSN:1756-8722, 1756-8722
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by monoclonal plasma cells. The key to treatment is to achieve a deep hematologic remission in order to improve organ function or reverse organ dysfunction. Conventional treatment has not been able to fully meet the treatment needs of patients with AL, while therapies targeting malignant plasma cells or amyloid have potentially improved treatment outcomes. This study provides an overview of the latest reports on targeted therapies for AL amyloidosis from the 2024 ASH Annual Meeting.
AbstractList Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by monoclonal plasma cells. The key to treatment is to achieve a deep hematologic remission in order to improve organ function or reverse organ dysfunction. Conventional treatment has not been able to fully meet the treatment needs of patients with AL, while therapies targeting malignant plasma cells or amyloid have potentially improved treatment outcomes. This study provides an overview of the latest reports on targeted therapies for AL amyloidosis from the 2024 ASH Annual Meeting.
Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by monoclonal plasma cells. The key to treatment is to achieve a deep hematologic remission in order to improve organ function or reverse organ dysfunction. Conventional treatment has not been able to fully meet the treatment needs of patients with AL, while therapies targeting malignant plasma cells or amyloid have potentially improved treatment outcomes. This study provides an overview of the latest reports on targeted therapies for AL amyloidosis from the 2024 ASH Annual Meeting.Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by monoclonal plasma cells. The key to treatment is to achieve a deep hematologic remission in order to improve organ function or reverse organ dysfunction. Conventional treatment has not been able to fully meet the treatment needs of patients with AL, while therapies targeting malignant plasma cells or amyloid have potentially improved treatment outcomes. This study provides an overview of the latest reports on targeted therapies for AL amyloidosis from the 2024 ASH Annual Meeting.
Abstract Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by monoclonal plasma cells. The key to treatment is to achieve a deep hematologic remission in order to improve organ function or reverse organ dysfunction. Conventional treatment has not been able to fully meet the treatment needs of patients with AL, while therapies targeting malignant plasma cells or amyloid have potentially improved treatment outcomes. This study provides an overview of the latest reports on targeted therapies for AL amyloidosis from the 2024 ASH Annual Meeting.
Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by monoclonal plasma cells. The key to treatment is to achieve a deep hematologic remission in order to improve organ function or reverse organ dysfunction. Conventional treatment has not been able to fully meet the treatment needs of patients with AL, while therapies targeting malignant plasma cells or amyloid have potentially improved treatment outcomes. This study provides an overview of the latest reports on targeted therapies for AL amyloidosis from the 2024 ASH Annual Meeting. Keywords: Immunoglobulin light chain amyloidosis, Targeted therapies, Clinical trials
ArticleNumber 28
Audience Academic
Author Zhu, Hong-Hu
Bu, Qiling
Chen, Wenming
Author_xml – sequence: 1
  givenname: Qiling
  surname: Bu
  fullname: Bu, Qiling
  organization: Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University
– sequence: 2
  givenname: Hong-Hu
  surname: Zhu
  fullname: Zhu, Hong-Hu
  email: zhuhhdoc@163.com
  organization: Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Chinese Institutes for Medical Research
– sequence: 3
  givenname: Wenming
  surname: Chen
  fullname: Chen, Wenming
  email: 13910107759@163.com
  organization: Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40055824$$D View this record in MEDLINE/PubMed
BookMark eNp9Ul1vFCEUnZga-6F_wAdDYmJ8mQozw8D40mwatU0afVCfCQN3ZtkwsALTpP9eplvbXWMMIVwu5x64h3NaHDnvoCheE3xOCG8_RFLjhpa4ypO0nJTsWXFCGG1LzqrqaC8-Lk5j3GDckq7CL4rjBmNKedWcFOmrvwWLkgwjJNAorSHIrYGIBh-QmabZ-dH6frbGIWvGdUJqLXMspzvrjfbRxI_IygQxoXmrlwANwU8LE6pw1aDV9ysknZulRRNAMm58WTwfpI3w6mE9K35-_vTj8qq8-fbl-nJ1Uyra4VR27UC1HjRWTHeUdT1hWlM9SOhrgKFmSnLeqqqvK5b3FHKeQkelamtVYVKfFdc7Xu3lRmyDmWS4E14acZ_wYRQyJKMsiF4phRuCtYa2aVreUwmcNhoT3A90UJnrYse1nfsJtAKXgrQHpIcnzqzF6G9F_ire8a7JDO8fGIL_NWe9xGSiAmulAz9HUS_fxThly8Pf_gXd-Dm4rJWoc2OZsGPsCTXK3IFxg88Xq4VUrHidX04YWa49_wcqDw2TUdlRg8n5g4J3ewVrkDato7dzMt7FQ-CbfUketfjjrgyodgAVfIwBhkcIwYsurdhZWGQLi3sLi6WrelcUM9iNEJ56_0_Vb1H18zY
Cites_doi 10.1182/blood-2024-208341
10.1182/blood-2024-204346
10.1182/blood-2024-198256
10.1182/blood-2024-208282
10.1182/blood-2024-202246
10.1056/NEJMoa2028631
10.1182/blood-2024-202091
10.1182/blood-2024-203254
10.1182/blood-2024-205077
10.1182/blood-2024-202713
10.1182/blood-2024-202932
10.1182/blood-2024-204700
ContentType Journal Article
Copyright The Author(s) 2025
2025. The Author(s).
COPYRIGHT 2025 BioMed Central Ltd.
2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2025 2025
Copyright_xml – notice: The Author(s) 2025
– notice: 2025. The Author(s).
– notice: COPYRIGHT 2025 BioMed Central Ltd.
– notice: 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2025 2025
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13045-025-01681-7
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
ProQuest Databases
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE




Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: Open Access: DOAJ - Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-8722
EndPage 4
ExternalDocumentID oai_doaj_org_article_bccc0410dde64468b5ae854d010bf5fc
PMC11889894
A830101714
40055824
10_1186_s13045_025_01681_7
Genre Letter
Review
GrantInformation_xml – fundername: Beijing Chao-Yang Hospital Clinical Research Incubation Program
  grantid: CYFH202313
GroupedDBID ---
0R~
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
ABDBF
ABUWG
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M~E
O5R
O5S
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
~8M
AAYXX
AFFHD
CITATION
ALIPV
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
M48
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c590t-96f5ddfd0c7d9579b17dd5dfaeb3eef37ca886c2b327eef5eeb35e95ac63c2013
IEDL.DBID RSV
ISICitedReferencesCount 0
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001439800600002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1756-8722
IngestDate Tue Oct 14 19:05:51 EDT 2025
Tue Nov 04 02:04:19 EST 2025
Fri Sep 05 08:22:38 EDT 2025
Sun Oct 19 00:07:40 EDT 2025
Tue Nov 11 10:51:56 EST 2025
Tue Nov 04 18:13:06 EST 2025
Thu May 22 21:23:20 EDT 2025
Mon Jul 21 05:55:37 EDT 2025
Sat Nov 29 08:15:29 EST 2025
Sat Sep 06 07:24:26 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Targeted therapies
Clinical trials
Immunoglobulin light chain amyloidosis
Language English
License 2025. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c590t-96f5ddfd0c7d9579b17dd5dfaeb3eef37ca886c2b327eef5eeb35e95ac63c2013
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Correspondence-4
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
OpenAccessLink https://link.springer.com/10.1186/s13045-025-01681-7
PMID 40055824
PQID 3201889977
PQPubID 54946
PageCount 4
ParticipantIDs doaj_primary_oai_doaj_org_article_bccc0410dde64468b5ae854d010bf5fc
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11889894
proquest_miscellaneous_3175678571
proquest_journals_3201889977
gale_infotracmisc_A830101714
gale_infotracacademiconefile_A830101714
gale_healthsolutions_A830101714
pubmed_primary_40055824
crossref_primary_10_1186_s13045_025_01681_7
springer_journals_10_1186_s13045_025_01681_7
PublicationCentury 2000
PublicationDate 2025-03-07
PublicationDateYYYYMMDD 2025-03-07
PublicationDate_xml – month: 03
  year: 2025
  text: 2025-03-07
  day: 07
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Journal of hematology and oncology
PublicationTitleAbbrev J Hematol Oncol
PublicationTitleAlternate J Hematol Oncol
PublicationYear 2025
Publisher BioMed Central
BioMed Central Ltd
Springer Nature B.V
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: Springer Nature B.V
– name: BMC
References E Kastritis (1681_CR2) 2024; 144
E Lebel (1681_CR7) 2024; 144
S Ailawadhi (1681_CR9) 2024; 144
TL Parker (1681_CR4) 2024; 144
JS Wall (1681_CR11) 2024; 144
P Mollee (1681_CR5) 2024; 144
B Qin (1681_CR12) 2024; 144
E Kastritis (1681_CR3) 2024; 144
K Shen (1681_CR8) 2024; 144
E Kastritis (1681_CR6) 2024; 144
E Kastritis (1681_CR1) 2021; 385
J Fu (1681_CR10) 2024; 144
References_xml – volume: 144
  start-page: 3378
  issue: Supplement 1
  year: 2024
  ident: 1681_CR4
  publication-title: Blood
  doi: 10.1182/blood-2024-208341
– volume: 144
  start-page: 893
  issue: Supplement 1
  year: 2024
  ident: 1681_CR8
  publication-title: Blood
  doi: 10.1182/blood-2024-204346
– volume: 144
  start-page: 894
  issue: Supplement 1
  year: 2024
  ident: 1681_CR7
  publication-title: Blood
  doi: 10.1182/blood-2024-198256
– volume: 144
  start-page: 4641
  issue: Supplement 1
  year: 2024
  ident: 1681_CR11
  publication-title: Blood
  doi: 10.1182/blood-2024-208282
– volume: 144
  start-page: 3372
  issue: Supplement 1
  year: 2024
  ident: 1681_CR12
  publication-title: Blood
  doi: 10.1182/blood-2024-202246
– volume: 385
  start-page: 46
  issue: 1
  year: 2021
  ident: 1681_CR1
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2028631
– volume: 144
  start-page: 360
  issue: Supplement 1
  year: 2024
  ident: 1681_CR10
  publication-title: Blood
  doi: 10.1182/blood-2024-202091
– volume: 144
  start-page: 1927
  issue: Supplement 1
  year: 2024
  ident: 1681_CR6
  publication-title: Blood
  doi: 10.1182/blood-2024-203254
– volume: 144
  start-page: 891
  issue: Supplement 1
  year: 2024
  ident: 1681_CR2
  publication-title: Blood
  doi: 10.1182/blood-2024-205077
– volume: 144
  start-page: 1022
  issue: Supplement 1
  year: 2024
  ident: 1681_CR9
  publication-title: Blood
  doi: 10.1182/blood-2024-202713
– volume: 144
  start-page: 1979
  issue: Supplement 1
  year: 2024
  ident: 1681_CR3
  publication-title: Blood
  doi: 10.1182/blood-2024-202932
– volume: 144
  start-page: 892
  issue: Supplement 1
  year: 2024
  ident: 1681_CR5
  publication-title: Blood
  doi: 10.1182/blood-2024-204700
SSID ssj0061920
Score 2.3795898
SecondaryResourceType review_article
Snippet Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by...
Abstract Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 28
SubjectTerms Amyloid
Amyloidosis
Antigens
Cancer Research
Clinical trials
Conferences, meetings and seminars
Correspondence
Drug dosages
Hematology
Humans
Immunoglobulin light chain amyloidosis
Immunoglobulin Light Chains - metabolism
Immunoglobulin Light-chain Amyloidosis - drug therapy
Immunoglobulin Light-chain Amyloidosis - therapy
Immunoglobulins
Latest updates from major conferences
Light
Light chains
Medicine
Medicine & Public Health
Molecular Targeted Therapy - methods
Monoclonal antibodies
Multiple myeloma
Oncology
Peptides
Plasma cells
Remission
Response rates
Targeted therapies
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQVSEuiPIMFDASEgeI6jz8CLcFUfUAKyQe6s1ybEddaTepNtn-fmbsZGmKEBduu_Fj43l4ZtYznwl5zWrhbQ0cYEaItOSVT2vRVKnwvDLMOsUDkPbPz3K5VOfn1ddrV31hTliEB46EO6mttazMGKghmG6ham48TOAgjqgb3ljcfZmspmAq7sEYFbCpREaJkz7DA8EUr24FF0dlqZyZoYDW_-eefM0o3UyYvHFqGozR6T1yd_Qi6SK-_RG55dv75PaX8Zz8ARmW3ZVf05jm7R2NVVYQFFPwUekKa0I6hALBNHS6xvic2gsDn80GAviV6_pV_56u0Q8d6O4S_xWAodtugzPRHCwuXXw7oxHQlG58qJt-SH6cfvr-8Swd71dILa_YkFai4c41jlnp8LSuzqRz3DUGAmzvm0Jao5SweV3kEr5zD8-5r7ixorDgOBSPyEHbtf4Jod6C6yTqnFvwFwpfGmY4sMC43DWqci4hbydy68sIo6FD-KGEjszRwBwdmKNlQj4gR_Y9EQI7PADB0KNg6H8JRkJeIj91rCfdK7JeqAJx9WRWJuRN6IGqDGy1ZqxIgCUhKNas5_GsJ6ignTdPMqPHLaDXBVBIQTQrYTmv9s04EtPaWt_toA84b-AtcJkl5HEUsf2iS4RHUzlMrmbCN6PKvKVdXQSA8Ax_WFUw9N0kp7_f6-9kf_o_yP6M3MmDnhUpk8fkYNju_HNyaK-GVb99EbT0F9OrQh0
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Health & Medical Collection
  dbid: 7X7
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LjtMw0IIFIS7LcyGwgJGQOEC0efkRLqggVnuAComHerMc22EjtUm3SVfi75lx0ixZBBdubTxOa894Hp4XIS-igjtTAAYizXmYsdyFBS_zkDuW68hYyXwh7e8fxXwuF4v883Dh1g5hlTue6Bm1bQzekR-lIKkkGAdCvF2fhdg1Cr2rQwuNq-Qats1GOheL0eBC2yDaJcpIftTG6BYMsYErKDoyDsVEGPma_X9y5t9E0-WwyUu-Uy-Sjm_972Juk_1BGaWznnrukCuuvktufBrc7fdIN2_O3ZL20eLO0j5ZC2xrCqourTC1pMGKIhjNTpdo5lNzquGzXv1cNpVt2qp9Q5eoznZ0u8bLBZi6aVb4JpqA4KazLye0r4tKV86nX98n344_fH1_Eg5tGkLD8qgLc14ya0sbGWHR6VfEwlpmSw12unNlKoyWkpukSBMB35mD58zlTBueGtiI9IDs1U3tHhLqDGhgvEiYAbUjdZmONAMcapvYUubWBuTVDl9q3VfjUN6KkVz12FWAXeWxq0RA3iFKR0ispO0fNJsfajiYqjDGRFkcAZsH1ZDLgmkHBGrBTi1KVpqAPEOCUH1a6sgP1EymWJ5PxFlAXnoI5AhAF0YPiQ2wJKytNYE8nEDCSTbT4R21qIGTtOqCVALyfBzGmRgdV7tmCzCgA4LSwUQckAc9jY6LzrDKmkzg5XJCvZNdmY7U1amvMx7jD8scpr7eEfrF__r7tj_69zIek5uJP4JpGIlDstdttu4JuW7Ou6rdPPUH-BdMPE8m
  priority: 102
  providerName: ProQuest
Title Novel targeted therapies for immunoglobulin light chain amyloidosis: latest updates from the 2024 ASH annual meeting
URI https://link.springer.com/article/10.1186/s13045-025-01681-7
https://www.ncbi.nlm.nih.gov/pubmed/40055824
https://www.proquest.com/docview/3201889977
https://www.proquest.com/docview/3175678571
https://pubmed.ncbi.nlm.nih.gov/PMC11889894
https://doaj.org/article/bccc0410dde64468b5ae854d010bf5fc
Volume 18
WOSCitedRecordID wos001439800600002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: Open Access: BioMedCentral Open Access Titles
  customDbUrl:
  eissn: 1756-8722
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0061920
  issn: 1756-8722
  databaseCode: RBZ
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAON
  databaseName: Open Access: DOAJ - Directory of Open Access Journals
  customDbUrl:
  eissn: 1756-8722
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0061920
  issn: 1756-8722
  databaseCode: DOA
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1756-8722
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0061920
  issn: 1756-8722
  databaseCode: M~E
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: AUTh Library subscriptions: ProQuest Central
  customDbUrl:
  eissn: 1756-8722
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0061920
  issn: 1756-8722
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Health & Medical Collection
  customDbUrl:
  eissn: 1756-8722
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0061920
  issn: 1756-8722
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 1756-8722
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0061920
  issn: 1756-8722
  databaseCode: PIMPY
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVAVX
  databaseName: SpringerLINK Contemporary 1997-Present
  customDbUrl:
  eissn: 1756-8722
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0061920
  issn: 1756-8722
  databaseCode: RSV
  dateStart: 20081201
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3bbtMw1GIbQrxwvwRGMRISDxCRS30Jbx3aNCRWVRtM5clybIdFapOpaff9nOMkhQx4gJeqiY_T-vhccy4m5HWUc2dy2IFIcx6OWebCnBdZyB3LdGSsZL6R9vlnMZ3K-TybdUVhTZ_t3ockvaT2bC35-ybGoF6Ix6-CmSLjUOyQPVB3Eg9sOD077-UvegRRXx7zx3kDFeQ79f8uj39RSNeTJa9FTL0iOrr7f0u4R-50hiedtJRyn9xw1QNy66QLrT8k62l95Ra0zQx3lraFWeBHUzBraYllJDV2D8HMdbpAl56aCw3f9RJ8_tLWTdl8oAs0Xdd0c4kvEmDqql7ik2gCSppOzo5p2wOVLp0vtX5Evh4dfvl4HHZHMoSGZdE6zHjBrC1sZITFAF8eC2uZLTT45M4VqTBaSm6SPE0EXDMH95nLmDY8NWBrpI_JblVX7imhzoC1xfOEGTAxUjfWkWawc9omtpCZtQF52--Sumw7byjvsUiuWkQqQKTyiFQiIAe4kVtI7Jrtb9Sr76pjQpUbY6JxHIFIBzOQy5xpB8RowSfNC1aYgLxEMlBtCeqW99VEptiKT8TjgLzxEMj9QA1Gd0UMsCTsozWA3B9AAtea4XBPaqqTGo1KAUMSHGABy3m1HcaZmAlXuXoDMGDvgYHBRByQJy1lbhc9xo5qMoGHywHNDrAyHKnKC99TPMYflhlMfdeT7s__9Xe0P_s38OfkduKpPw0jsU9216uNe0Fumqt12axGZEfMhf-UI7J3cDidnY78OxK4mn06mX0beUb_AVm6SzU
linkProvider Springer Nature
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQMAL90tgMCOBeIBoudSxg4RQuUyd1lVIDNQ349gOi9Q2pWmH9qf4jZzjJB0Zgrc98JbEl8TOd272OceEPA2yxOoM_kCgksTvsdT6WZKnfmJZqgJtBHOJtL8M-WgkxuP04wb52cbCoFtlyxMdozalxjXynRgklQDjgPM38-8-nhqFu6vtERo1LPbtyQ8w2arXe-_h_z6Lot0Ph-8GfnOqgK9ZGiz9NMmZMbkJNDe4R5WF3BhmcgVmpbV5zLUSItFRFkcc7pmF58ymTOkk1vARMfR7gVwEPs7R2OPjtYGHtkjQBuaIZKcKcRvSxwNjQbESoc87ws-dEfCnJPhNFJ510zyzV-tE4O71_23ybpBrjbJN-zV13CQbdnaLXD5o3Aluk-WoPLYTWnvDW0PrYLTCVhRUeVpg6EyJGVPQW59OcBmD6iMF12p6MikLU1ZF9YpOUF1f0tUcF0-g6aKcYk80AsWE9j8NaJ33lU6tCy-_Qz6fy5jvks1ZObP3CbUaNMwki5gGtSq2PRUoBphRJjK5SI3xyIsWH3JeZxuRzkoTiazRJAFN0qFJco-8RQita2KmcPegXHyTDeORmdY66IUBiDFQfRORMWWBAA3Y4VnOcu2RbQSgrMNu1_xO9kWM6Qd52PPIc1cDOR7gUKsmcAOGhLnDOjW3OjWBU-lucYtO2XDKSp5C0yNP1sXYEr3_ZrZcQR3QcUGpYjz0yL2aJtaD7mEWORFB56JDLZ1Z6ZbMiiOXRz3EF4sUmr5sCev0u_4-7Q_-PYxtcmVweDCUw73R_kNyNXLkH_sB3yKby8XKPiKX9PGyqBaPHfOg5Ot5E9wvTFWwjQ
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdgoImX8TkIDGYkJB4gWr78Ed7KRzXEqCYNpr1Zju2wSm1Stemk_ffcOUlZBjwg3tr4nNTnu_Nd7-4XQl5FBXemgB2INOdhxnIXFrzMQ-5YriNjJfNA2qdHYjKRZ2f58ZUufl_t3qck254GRGmqmoOFLVsVl_xgFWOCL8RXsYLLIuNQ3CS3Miykx3j95LS3xRgdRH2rzB_nDY4jj9r_u22-cjhdL5y8lj31h9L47v8v5x7Z6RxSOmol6D654aoHZPtrl3J_SJpJfeFmtK0Yd5a2DVsQX1Nwd-kU20tqRBXBinY6w1CfmnMNn_X8clZPbb2art7RGbq0DV0v8A8GmLqs53gnmsDhTUcnh7TFRqVz51uwH5Hv40_fPhyG3asaQsPyqAlzXjJrSxsZYTHxV8TCWmZLDbG6c2UqjJaSm6RIEwHfmYPrzOVMG54a8EHSXbJV1ZV7Qqgz4IXxImEGXI_UZTrSDHZR28SWMrc2IG_6HVOLFpFD-UhGctUyUgEjlWekEgF5j5u6oUQ0bX-hXv5QnXKqwhgTgfiAqQf3kMuCaQdCaiFWLUpWmoDso0iotjV1YxPUSKYI0SfiLCCvPQVaBZAMo7vmBlgS4msNKPcGlKDNZjjci53qrMlKpcAhCYGxgOW83AzjTKyQq1y9BhrwA8HxYCIOyONWSjeLzhBpTSZwczmQ3wFXhiPV9Nxjjcf4YJnD1Le9GP_6XX9n-9N_I98n28cfx-ro8-TLM3In8YqQhpHYI1vNcu2ek9vmopmuli-8dv8E3yxQ7Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Novel+targeted+therapies+for+immunoglobulin+light+chain+amyloidosis%3A+latest+updates+from+the+2024+ASH+annual+meeting&rft.jtitle=Journal+of+hematology+and+oncology&rft.au=Bu%2C+Qiling&rft.au=Zhu%2C+Hong-Hu&rft.au=Chen%2C+Wenming&rft.date=2025-03-07&rft.pub=BioMed+Central&rft.eissn=1756-8722&rft.volume=18&rft.issue=1&rft_id=info:doi/10.1186%2Fs13045-025-01681-7&rft.externalDocID=10_1186_s13045_025_01681_7
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-8722&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-8722&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-8722&client=summon